Lupin gets approval to market Bimatroprost Ophthalmic Solution, 0.03%

From USFDA

Lupin announced that it has received final approval for its Bimatroprost Ophthalmic Solution, 0.03% from the United States Food & Drug Administration (FDA) to market a generic version of Allergen Inc.'s Lumigan Ophthalmic Solution 0.03%.

Powered by Capital Market - Live News